Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib

By Chahardouli Bahram   Zaker Farhad   Mousavi Seied Asadollah   Saffari Zeinab   Nadali Fatemeh   Ostadali Mohammadreza   Ghadimi Habibeh   Alimoghaddam Kamran   Ghavamzade Ardeshir   Rostami Shahrbano  

Hematology, Vol. 18, Iss. 6, 2013-11 ,pp. : 327-332

Maney Publishing

Access to resources Recommend Favorite

ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis

By Sacha T.   Hochhaus A.   Hanfstein B.   Muller M.C.   Rudzki Z.   Czopek J.   Wolska-Smolen T.   Czekalska S.   Salamanchuk Z.   Jakobczyk M.   Skotnicki A.B.  

Leukemia Research, Vol. 27, Iss. 12, 2003-12 ,pp. : 1163-1166

Elsevier

Access to resources Recommend Favorite

Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL⁺ cells

By Haririan Mahmoud   Kaviani Saeid   Soleimani Masoud   Ghaemi Soraya Rasi   Delalat Bahman   Atashi Amir  

Hematology, Vol. 17, Iss. 1, 2012-01 ,pp. : 28-34

Maney Publishing

Access to resources Recommend Favorite

Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells - the road taken

By Gaston I.   Stenberg P.E.   Bhat A.   Druker B.J.  

Experimental Hematology, Vol. 28, Iss. 1, 2000-01 ,pp. : 77-86

Elsevier

Access to resources Recommend Favorite

Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+ Leukemic Cells and Induces Apoptosis

By Gambacorti-Passerini C.   Le Coutre P.   Mologni L.   Fanelli M.   Bertazzoli C.   Marchesi E.   Di Nicola M.   Biondi A.   Corneo G.M.   Belotti D.   Pogliani E.   Lydon N.B.  

Blood Cells, Molecules, and Diseases, Vol. 23, Iss. 3, 1997-12 ,pp. : 380-394

Academic Press

Access to resources Recommend Favorite